Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | PER2 | O15055 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9409681 | 0.80 | POLB (0.41) | KMT2AMEN1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL9409685 | 0.78 | CHRM2 (0.45) | KMT2AMEN1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL9409672 | 0.77 | CHRM2 (0.58) | CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL16059829 | 0.77 | — | — | |
| SCHEMBL20523332 | 0.76 | DPP4 (0.36) | ALDH1A1CYP2C9CYP2C19CYP1A2CYP2D6 | |
| SCHEMBL9409701 | 0.75 | CHRM2 (0.36) | KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2705008 | 0.75 | — | — | |
| SCHEMBL7844310 | 0.75 | — | — | |
| SCHEMBL301524 | 0.72 | — | — | |
| SCHEMBL13236669 | 0.71 | ALDH1A1 (0.50) | KMT2AMEN1SMN1; SMN2POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825155-B2 | Oxindole derivative as feeding control agent | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-11-02 | — | — | US | disclosed |
| US-7825155-B2 | Oxindole derivative as feeding control agent | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-11-02 | — | — | US | disclosed |
| US-20090131398-A1 | OXINDOLE DERIVATIVE AS FEEDING CONTROL AGENT | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131398-A1 | OXINDOLE DERIVATIVE AS FEEDING CONTROL AGENT | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-5137905-A | Cholinergic agonists; analgesics; cognition activators | THE UPJOHN COMPANY (US) | 1992-08-11 | — | — | US | disclosed |
| EP-0440670-A1 | HETEROCYCLIC ACETYLENIC AMINES HAVING CENTRAL NERVOUS SYSTEM ACTIVITY. | UPJOHN CO (US) | 1991-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131398-A1 | OXINDOLE DERIVATIVE AS FEEDING CONTROL AGENT | GPR119, OXTR, CCKAR | KMT2A 1509/4885MEN1 2230/4885SMN1; SMN2 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.